EULAR: Biologic tapering in RA shows cost efficacy

ROME – Patients with rheumatoid arthritis in sustained remission on a biologic drug successfully remained in remission most of the time while gradually stepping down to a longer dosage interval or...

Field of Interest: Rheumatology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.